Fig. 2: Efferocytosis blockade by mU@OMVs for the release of TAAs.
a Western blot analysis of phosphorylation of MerTK (p-MerTK) in M2 macrophages after mU@OMVs treatment for 2 h. b Schematic of mU@OMVs-mediated efferocytosis inhibition and antigen release. c CLMS imaging of the engulfment of AC (carboxyfluorescein succinimidyl ester (CFSE)-labeled, green) by macrophages (APC-conjugated anti-CD11b labeled, red) after a 6-h incubation. M: M2 macrophages; LC: living B16F10 cells; AC: apoptotic B16F10 cells. Scale bar: 50 μm. a, c Data are representative of three biological replicates. d, e Flow cytometry and quantification of phagocytosis after different treatments. f HMGB1 levels in the supernatants were determined by ELISA after further 18 h culture. g, h Relative abundance of tumor mutational proteins, DAMPs, predicted neoantigens and neoantigens captured by mU@OMVs. Proteins-adsorbed mU@OMVs were collected for proteomics analysis and identified according to the previous report21,46,47. Data in e, f are presented as mean ± s.d. (n = 3 biologically independent samples). Statistically significant differences between groups were identified by unpaired two-tailed Student’s t-test. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, n.s., not significant. Source data are provided as a Source Data file.
